Sales: $2.4 billion
Key Personnel: Emma Walmsley, chief executive officer; Roger Connor, president, global manufacturing and supply; Simon Dingemans, chief financial officer; Brian McNamara, chief executive officer, GSK Consumer Healthcare; David Redfern, chief strategy officer; Dr. Patrick Vallance, president, R&D.
Major Products: Oral care—Sensodyne, Polident/Corega, Parodontax, Biotene and Aquafresh.
New Products: Sensodyne Deep Clean toothpaste.
Comments: GlaxoSmithKline is the No. 3 player in the global oral care segment. Last year, Sensodyne became the company’s first £1 billion consumer health care brand, which makes it the third-largest product by sales in the GSK portfolio.
For Q1 2017, sales rose in every segment, although consumer healthcare sales rose just 2%. However, oral care sales rose 7% to $715 million in the period. Sensodyne drove sales higher, as did Parodontax, reflecting gains in Europe and International markets, as well as the brand’s US launch. The newest toothpaste in the Sensodyne lineup is Deep Clean, which is said to work inside the tooth to help calm the nerves for 24 hours, while providing all of the benefits of regular toothpaste.
On April 1, Emma Walmsley became CEO at GSK, succeeding Andrew Witty who retired. Walmsley had been president of the consumer healthcare division. She joined GSK in 2010 from L’Oréal, where she held a variety of marketing and management roles in the UK, Europe and US.
GSK may be leading the way in oral care research, but the company is always looking for outside help. At innovation.gsk.com, potential partners can view a list of current oral care needs, which include plaque-reducing or plaque-inhibiting solutions, gum health and enamel health.